ClinicalTrials.gg
CompletedNCT00382889Updated Aug 3, 2020

As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma

A Phase 3 interventional study of beclomethasone/salbutamol combination and beclomethasone in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 25 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
7th of 40
480 · median 67
Started
2002
the only one that year
Phase 3
20 of 40
none open now
Registered
7th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 7th largest by enrollment, is the only one that started in 2002, is one of 20 in phase 3, and was the 7th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

The aim of this study is to reveal that inhaled corticosteroid therapy combined with a short-acting beta2- agonist given on a symptom driven basis is as effective as traditional asthma therapy.

Thus, three advantages will be achieved:

  1. better compliance with treatment since patients will most likely have to administer the treatment less frequently,
  2. maximum pharmacological effect with the least amount of drug and
  3. less economic burden on health care providers.
Read the detailed description

Asthma is widely recognised as a chronic inflammatory disorder of the airways. The 1997 American National Heart Lung and Blood Institute (NHLBI) Guidelines states that a firm scientific basis exists to indicate that asthma results from complex interactions among inflammatory cells, mediators and the cells and tissues resident in the airways.

Despite the existence of effective therapy people still die from asthma. It is pertinent to state that the clinical effect of a drug is not only dependent on the specific action of the drug, but also on the patient's way of using it. Therefore, compliance is an important factor especially for chronic disorders such as asthma. Indeed, non compliance with asthma therapy is a serious problem. It has been reported that drug side effects, lifestyle, social and economic factors, method of drug delivery and dosing are factors that contribute to poor compliance. The consequences of poor compliance lead to increased morbidity due to increased symptoms and asthma exacerbation.

The NHLBI Guidelines recommend daily treatment for patients with mild persistent asthma with inhaled glucocorticoids (200-500mcg/die) and short-acting bronchodilators as needed but no more than 3-4 times a day.

Comparisons: beclomethasone dipropionate 250 mg combined with salbutamol 100 mg "as needed", vs salbutamol 100 mg alone "as needed", vs beclomethasone 250 mg twice a day plus salbutamol 100 mg "as needed" and vs beclomethasone dipropionate 250 mg combined with salbutamol 100 mg twice a day plus salbutamol 100 mg "as needed", in the treatment of patients with mild persistent asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Anti-Asthmatic Agents
  • corticosteroids
  • symptom-driven
  • beclomethasone
  • salbutamol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of mild persistent asthma as defined by NHLBI/WHO 97; for at least 6 months;
  • ³ 75% of predicted normal value;
  • Positive response to the reversibility test to b2 agonist, defined as an increase > 12% in the FEV1 measured 30 minutes following 2 puffs (2x100mg) of inhaled Salbutamol spray, or positive methacholine challenge (PC20\<8mg/ml or PD20\<1 mg) within the previous 6 months;
  • Stable asthma. Asthma is defined stable if none of the following occurred during the last 14 days of the run-in period: diurnal variation of more than 20% in PEF on 2 consecutive days; use of four or more inhalations of b2 agonist per day on two consecutive days; need the use of oral ;

Exclusion criteria

Exclusion Criteria:

  • as defined by the ERS - Consensus Statement;
  • Patients with more than 10 packs/year of cigarettes history and current smokers;
  • History of near fatal asthma and/or admission in intensive care unit because of asthma;
  • One severe exacerbation during the run-in period;
  • Three or more courses of oral or hospitalisation for asthma during the previous 1 year;
  • Patients treated with more than 500 mcg/day of beclomethasone or equivalent for more than 6 months in the previous last year;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
480 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary outcome for comparison across treatment groups was the mean value of morning PEF measured during the last 2 weeks of treatment (weeks 23-24)

Secondary outcomes

  1. Number of exacerbations

  2. Time to first severe exacerbation

  3. Improvement of asthma symptoms (symptom scores)

  4. Need for short acting b2 agonists

  5. Variation of respiratory parameters (FEV1, PEF, FVC, FEV1/FVC, FEF25-75) immediately before and 30 min after a test with a short-acting b2 agonist

  6. evening PEF

  7. Diurnal variability of PEF

  8. Nocturnal asthma (nocturnal awakening because of asthma)

  9. Nights and days without asthma symptoms (score 0)

07

Study locations

25 sites
  • Ambulance for pediatrics and Pneumology
    Wien, Austria
  • Pulmologisches Zentrum Der Stadt Wien
    Wien, Austria
  • Dip. di Pneumologia - Osp. Tommaselli
    Catania, Italy
  • Nuove Cliniche Arcispedale S.Anna
    Ferrara, Italy
  • DIMI - Dip. Medicina Interna - Univ. di Genova - clinica di malattie apparato respiratorio e allergologico
    Genova, Italy
  • Dipartimento di scienze mediche oncologiche e radiologiche - sez. malattie apparato respiratorio
    Modena, Italy
  • Univ. di Padova - Dipartimento di medicina ambientale e sanità pubblica
    Padova, Italy
  • Istituto di Fisiopatologia Respiratoria CNR - Ospedale Cervello
    Palermo, Italy
  • Clinica Pneumologica padiglione Rasori - Univ. di Parma
    Parma, Italy
  • Clinica di Malattie dell'Apparato Respiratorio dell'Univ. di Pavia - Policlinico S. Matteo
    Pavia, Italy
  • Reparto Fisiologia Respiratoria - dip. Cardiotoracico - Ospedale Cisanello
    Pisa, Italy
  • Outpatient Clinic of Internal Diseases and Allergology
    Bialystok, Poland
  • Specialist Group Medex
    Bielsko Biala, Poland
  • Clinic of Internal Diseases Atopia Al.
    Krakow, Poland
  • Pulmonologic Clinic - Poludnie os. Krakowiakòw
    Krakow, Poland
  • Clinic of Pneumology and Allergology
    Lòdz, Poland
  • Clinic of Tubercolosis and Lung Diseases
    Lòdz, Poland
  • Clinic of Pneumology - Institute of Internal Medicine of Medical Academy
    Lódz, Poland
  • Institute of Occupational Medicine - Clinic of Occupational Disesase
    Lódz, Poland
  • Clinic of Infection Diseases and Allergology - Central Clinical Hospital of Military Medical Academy
    Warszawa, Poland
  • Clinic of Pneumology and Allergology A.M.
    Warszawa, Poland
  • Clinic of Pneumology and Allergology of Medical Academy
    Warszawa, Poland
  • Hospital Vall d'Hebron de Barcelona
    Barcelona, 08035, Spain
  • H.General de Vic, Servicio de Neumologia
    Barcelona, 08500, Spain
  • Hospital de Matarò
    Mataro, 08304, Spain
08

References and documents

Publications

  • Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52. doi: 10.1056/NEJMoa063861. PubMed 17507703 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2006
First posted
Oct 2, 2006
Start
Aug 2002
Completion
Sep 2004
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00382889
First posted
Oct 2, 2006
Start date
Aug 2002
Completion
Sep 2004
Last update
Aug 3, 2020

Study contacts

Leonardo M Fabbri, MD
principal investigator · Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Oncologia, Ematologia e Pneumologia, Università di Modena e Reggio Emilia, Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Albuterol

Start the discussion